AZN logo

AZN

AstraZeneca PLC

$187.03
-$2.72(-1.43%)
59
Overall
50
Value
63
Tech
65
Quality
How is this score calculated?
Market Cap
$571.12B
Volume
2.12M
52W Range
$137.23 - $212.71
Target Price
$219.39

Company Overview

Mkt Cap$571.12BPrice$187.03
Volume2.12MChange-1.43%
P/E Ratio55.9Open$188.22
Revenue$58.7BPrev Close$189.75
Net Income$10.2B52W Range$137.23 - $212.71
Div Yield5.30%Target$219.39
Overall59Value50
Quality65Technical63

No chart data available

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Major

Latest News

AstraZeneca Extends COPD Bet With New Long‑Term Tozorakimab Safety Study

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new ROMEO study tracks how safe its COPD drug tozoraki...

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago

AstraZeneca Advances First-in-Human AZD8359 Study in Metastatic Prostate Cancer

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

Solomon Oladipupo7 days ago

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

Solomon Oladipupo7 days ago

FDA approvals extend Enhertu into curative-intent HER2-positive early breast cancer

TipRanks UK Auto-Generated Newsdesk7 days ago
ABCD
1SymbolPriceChangeVol
2AZN$187.03-1.4%2.12M
3
4
5
6

Get AstraZeneca PLC Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.